{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:22:53Z","timestamp":1740374573632,"version":"3.37.3"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003669","name":"Korea Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["2021-NI-029-00"],"award-info":[{"award-number":["2021-NI-029-00"]}],"id":[{"id":"10.13039\/501100003669","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003653","name":"Korea National Institute of Health","doi-asserted-by":"publisher","award":["6600-6634-332","2022-NI-029-00"],"award-info":[{"award-number":["6600-6634-332","2022-NI-029-00"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Immunological Methods"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jim.2024.113787","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T06:20:24Z","timestamp":1733984424000},"page":"113787","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Plaque reduction neutralization test for smallpox vaccines: Laboratory optimization and validation method for immunogenicity assessment"],"prefix":"10.1016","volume":"536","author":[{"given":"Hyun-Jung","family":"Kong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dokeun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Ho","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jim.2024.113787_bb0005","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3121\/cmr.1.2.87","article-title":"Smallpox vaccine: the good, the bad, and the ugly","volume":"1","author":"Belongia","year":"2003","journal-title":"Clin. Med. Res."},{"key":"10.1016\/j.jim.2024.113787_bb0010","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/9781118971147.ch5","article-title":"Q2 (R1) validation of analytical procedures: text and methodology","author":"Borman","year":"2017","journal-title":"ICH Quality Guidelin."},{"key":"10.1016\/j.jim.2024.113787_bb0020","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.vaccine.2007.10.046","article-title":"Plaque reduction neutralization test for measles antibodies: description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination","volume":"26","author":"Cohen","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2024.113787_bb0025","first-page":"1","article-title":"Smallpox vaccination and adverse reactions; guidance for clinicians","volume":"52","author":"Cono","year":"2003","journal-title":"MMWR Recomm. Rep."},{"key":"10.1016\/j.jim.2024.113787_bb0030","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/tmi.12737","article-title":"Seroepidemiology: an underused tool for designing and monitoring vaccination programmes in low- and middle-income countries","volume":"21","author":"Cutts","year":"2016","journal-title":"Trop. Med. Int. Health"},{"key":"10.1016\/j.jim.2024.113787_bb0035","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jacc.2004.05.004","article-title":"Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination","volume":"44","author":"Eckart","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"author":"Fenner","key":"10.1016\/j.jim.2024.113787_bb0040"},{"key":"10.1016\/j.jim.2024.113787_bb0045","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1086\/375825","article-title":"Smallpox vaccination: a review, part II. Adverse events","volume":"37","author":"Fulginiti","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jim.2024.113787_bb0050","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1542\/peds.55.3.342","article-title":"Smallpox vaccination reactions, prophylaxis, and therapy of complications","volume":"55","author":"Goldstein","year":"1975","journal-title":"Pediatrics"},{"key":"10.1016\/j.jim.2024.113787_bb0055","article-title":"A multicenter, open-label, controlled phase II study to evaluate safety and immunogenicity of MVA smallpox vaccine (IMVAMUNE) in 18\u201340 year old subjects with diagnosed atopic dermatitis","volume":"10","author":"Greenberg","year":"2015","journal-title":"PLoS One"},{"year":"1966","series-title":"Diagnostic Methods in Clinical Virology","author":"Grist","key":"10.1016\/j.jim.2024.113787_bb0060"},{"key":"10.1016\/j.jim.2024.113787_bb0065","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1001\/jama.289.24.3283","article-title":"Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel","volume":"289","author":"Halsell","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jim.2024.113787_bb0070","doi-asserted-by":"crossref","first-page":"D7","DOI":"10.1016\/j.vaccine.2011.06.080","article-title":"The eradication of smallpox\u2013an overview of the past, present, and future","volume":"29","author":"Henderson","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2024.113787_bb0085","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.vaccine.2024.01.064","article-title":"Live attenuated smallpox vaccine candidate (KVAC103) efficiently induces protective immune responses in mice","volume":"42","author":"Hwang","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2024.113787_bb0090","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1016\/j.vaccine.2010.06.063","article-title":"A randomized, double-blind, controlled clinical trial to evaluate the efficacy and safety of CJ-50300, a newly developed cell culture-derived smallpox vaccine, in healthy volunteers","volume":"28","author":"Jang","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2024.113787_bb0095","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0092-1157(87)80013-6","article-title":"The effect of the virus-serum incubation period upon vaccinia virus serum neutralization titers","volume":"15","author":"Katz","year":"1987","journal-title":"J. Biol. Stand."},{"key":"10.1016\/j.jim.2024.113787_bb0105","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.coi.2009.04.004","article-title":"The immunology of smallpox vaccines","volume":"21","author":"Kennedy","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jim.2024.113787_bb0110","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.1016\/j.vaccine.2013.08.071","article-title":"An open-label, single arm, phase III clinical study to evaluate the efficacy and safety of CJ smallpox vaccine in previously vaccinated healthy adults","volume":"31","author":"Kim","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2024.113787_bb0120","article-title":"Complications of smallpox vaccination, 1968: results of ten statewide surveys","volume":"303\u2013309","author":"Lane","year":"1970","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jim.2024.113787_bb0125","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1016\/j.vaccine.2021.06.060","article-title":"Development of an attenuated smallpox vaccine candidate: the KVAC103 strain","volume":"39","author":"Lim","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2024.113787_bb0130","doi-asserted-by":"crossref","first-page":"214","DOI":"10.4269\/ajtmh.1972.21.214","article-title":"A prospective study of serum antibody and protection against smallpox","volume":"21","author":"Mack","year":"1972","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.jim.2024.113787_bb0135","first-page":"375","article-title":"The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defense mechanism (author\u2019s transl)","volume":"167","author":"Mayr","year":"1978","journal-title":"Zentralbl. Bakteriol. B."},{"key":"10.1016\/j.jim.2024.113787_bb0140","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1099\/vir.0.2008\/004440-0","article-title":"Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax","volume":"89","author":"Midgley","year":"2008","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.jim.2024.113787_bb0145","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1128\/JCM.41.7.3154-3157.2003","article-title":"Improved assay to detect neutralizing antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccine","volume":"41","author":"Newman","year":"2003","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jim.2024.113787_bb0150","doi-asserted-by":"crossref","first-page":"D74","DOI":"10.1016\/j.vaccine.2012.01.080","article-title":"The expanded programme on immunization: a lasting legacy of smallpox eradication","volume":"29","author":"Okwo-Bele","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2024.113787_bb0155","first-page":"ofv040","article-title":"Safety and immunogenicity of modified vaccinia Ankara-Bavarian Nordic smallpox vaccine in vaccinia-naive and experienced human immunodeficiency virus-infected individuals: an open-label, controlled clinical phase II trial. Open forum","volume":"2","author":"Overton","year":"2015","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.jim.2024.113787_bb0160","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1817307","article-title":"Phase 3 efficacy trial of modified vaccinia Ankara as a vaccine against smallpox","volume":"381","author":"Pittman","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jim.2024.113787_bb0165","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1086\/589862","article-title":"Correlates of vaccine-induced immunity","volume":"47","author":"Plotkin","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jim.2024.113787_bb0170","doi-asserted-by":"crossref","first-page":"7321","DOI":"10.1016\/j.vaccine.2022.10.078","article-title":"Serological responses to the MVA-based JYNNEOS monkeypox vaccine in a cohort of participants from the Democratic Republic of Congo","volume":"40","author":"Priyamvada","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2024.113787_bb0175","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jama.2009.289","article-title":"Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8","volume":"301","author":"Saito","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jim.2024.113787_bb0180","doi-asserted-by":"crossref","first-page":"961","DOI":"10.4161\/hv.21080","article-title":"A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication","volume":"8","author":"Verardi","year":"2012","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.jim.2024.113787_bb0185","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.vaccine.2005.11.022","article-title":"Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine","volume":"24","author":"Vollmar","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2024.113787_bb0190","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.vaccine.2009.11.030","article-title":"A randomized, double-blind, dose-finding phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE\u00ae","volume":"28","author":"von Krempelhuber","year":"2010","journal-title":"Vaccine"},{"author":"World Health Organization","key":"10.1016\/j.jim.2024.113787_bb0200"},{"key":"10.1016\/j.jim.2024.113787_bb0205","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1080\/22221751.2022.2095309","article-title":"Monkeypox virus emerges from the shadow of its more infamous cousin: family biology matters","volume":"11","author":"Xiang","year":"2022","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.jim.2024.113787_bb0215","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-022-02090-w","article-title":"Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals","volume":"29","author":"Zaeck","year":"2023","journal-title":"Nat. Med."}],"container-title":["Journal of Immunological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175924001728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175924001728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T18:08:00Z","timestamp":1740334080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022175924001728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":36,"alternative-id":["S0022175924001728"],"URL":"https:\/\/doi.org\/10.1016\/j.jim.2024.113787","relation":{},"ISSN":["0022-1759"],"issn-type":[{"type":"print","value":"0022-1759"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plaque reduction neutralization test for smallpox vaccines: Laboratory optimization and validation method for immunogenicity assessment","name":"articletitle","label":"Article Title"},{"value":"Journal of Immunological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jim.2024.113787","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113787"}}